Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M6495 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| M6495 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| M6495 | DRUG | Subjects will receive M6495 on Day 1 |
| Placebo | DRUG | Subjects will receive placebo matched to M6495 on Day 1 |
Inclusion Criteria: * Subjects with Body Mass Index (BMI) of greater than or equal to (\>=) 18.5 and less than or equal to (=\<) 29.9 Kilogram per square meter (kg/m\^2), and a body weight between 50 and 100 kg at screening. * Subjects must agree to use effective method(s) of contraception during t...
M6495 is an investigational small molecule being studied in healthy volunteers. It is a first-in-human anti-ADAMTS-5 nanobody being evaluated for safety and tolerability. The drug is not approved for any disease and is in Phase 1 clinical development.
M6495 targets ADAMTS-5, an enzyme involved in cartilage breakdown. As an anti-ADAMTS-5 nanobody, it is designed to inhibit this target. The drug is being studied in a Phase 1 trial in healthy male volunteers to assess its safety profile.
M6495 is being developed by Merck & Company, Inc., traded on the New York Stock Exchange under the ticker MRK. The company is conducting a Phase 1 clinical trial of this investigational small molecule in healthy volunteers.
M6495 is in Phase 1 clinical development. It is an investigational drug, not approved by regulatory authorities. A first-in-human trial of M6495 in healthy volunteers has been completed, with results not yet reported.
M6495 has one completed Phase 1 clinical trial, NCT03224702, titled "First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers." This randomized, double-blind, placebo-controlled study enrolled 54 healthy male participants in Denmark.
M6495 is an anti-ADAMTS-5 nanobody, as described in the clinical trial title. The drug is a small molecule that targets ADAMTS-5. No other alternative names for M6495 have been disclosed.